Pharmaceuticals, Biotechnology and Life Sciences
Pfizer and Eli lilly have announced top-line results from a Phase 3 study evaluating tanezumab 2.5mg and 5 mg.
Pfizer and Eli Lilly have been testing tanezumab in patients with moderate-to-severe chronic low back pain (CLBP) in a Phase 3 study, with certain success, as tanezumab 10 mg met the primary endpoint by reducing pain at 16 weeks compared to placebo.
Eli Lilly has bought a biotech company focusing on pain management, CoLucid Pharmaceuticals for approximately $960 million, ($46.50 per share)…